Amicus Therapeutics 2025 Guidance: Expects Total Revenue Growth Of 17%-24%, Gross Margin In Mid 80% And GAAP Net Income Positive In Second-Half

Benzinga

2025/02/19

2025 Financial Guidance

To advance our strategy and expand our leadership in Fabry and Pompe disease, our financial guidance for 2025 is as follows:

Total Revenue Growth1	17% to 24%
Galafold Revenue Growth1	10% to 15%
Pombiliti + Opfolda Growth1	65% to 85%
Gross Margin	Mid 80%
Non-GAAP Operating Expenses4	$350M to $370M
GAAP Net Income	Positive during H2 2025

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2512105242"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2512105242\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2512105242?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-19 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2512105242","market":"us","top_or_hot":-1,"title":"Amicus Therapeutics 2025 Guidance: Expects Total Revenue Growth Of 17%-24%, Gross Margin In Mid 80% And GAAP Net Income Positive In Second-Half","media":"Benzinga","content":"<html><body><p><strong>2025 Financial Guidance</strong></p><p>To advance our strategy and expand our leadership in Fabry and Pompe disease, our financial guidance for 2025 is as follows:</p><figure><table><tbody><tr><td>Total Revenue Growth1</td><td>17% to 24%</td></tr><tr><td>Galafold Revenue Growth1</td><td>10% to 15%</td></tr><tr><td>Pombiliti + Opfolda Growth1</td><td>65% to 85%</td></tr><tr><td>Gross Margin</td><td>Mid 80%</td></tr><tr><td>Non-GAAP Operating Expenses4</td><td>$350M to $370M</td></tr><tr><td>GAAP Net Income</td><td>Positive during H2 2025</td></tr></tbody></table></figure></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amicus Therapeutics 2025 Guidance: Expects Total Revenue Growth Of 17%-24%, Gross Margin In Mid 80% And GAAP Net Income Positive In Second-Half</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmicus Therapeutics 2025 Guidance: Expects Total Revenue Growth Of 17%-24%, Gross Margin In Mid 80% And GAAP Net Income Positive In Second-Half\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time smaller\">2025-02-19 20:03</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<html><body><p><strong>2025 Financial Guidance</strong></p><p>To advance our strategy and expand our leadership in Fabry and Pompe disease, our financial guidance for 2025 is as follows:</p><figure><table><tbody><tr><td>Total Revenue Growth1</td><td>17% to 24%</td></tr><tr><td>Galafold Revenue Growth1</td><td>10% to 15%</td></tr><tr><td>Pombiliti + Opfolda Growth1</td><td>65% to 85%</td></tr><tr><td>Gross Margin</td><td>Mid 80%</td></tr><tr><td>Non-GAAP Operating Expenses4</td><td>$350M to $370M</td></tr><tr><td>GAAP Net Income</td><td>Positive during H2 2025</td></tr></tbody></table></figure></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FOLD","symbol_name":"愛美醫療","start_time":0,"source_url":"https://www.benzinga.com/news/earnings/25/02/43808868/amicus-therapeutics-2025-guidance-expects-total-revenue-growth-of-17-24-gross-margin-in-mid-80-and-","article_id":"2512105242","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2512105242","pubTimestamp":1739966627,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"2025 Financial GuidanceTo advance our strategy and expand our leadership in Fabry and Pompe disease, our financial guidance for 2025 is as follows:Total Revenue Growth117% to 24%Galafold Revenue Growth110% to","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"FOLD":"爱美医疗","TSS":"Total System Services"},"translate_title":"Amicus Therapeutics 2025年指引：预计下半年总收入增长17%-24%，毛利率在80%左右，GAAP净利润为正","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TSS":1,"FOLD":1},"content_text":"2025 Financial GuidanceTo advance our strategy and expand our leadership in Fabry and Pompe disease, our financial guidance for 2025 is as follows:Total Revenue Growth117% to 24%Galafold Revenue Growth110% to 15%Pombiliti + Opfolda Growth165% to 85%Gross MarginMid 80%Non-GAAP Operating Expenses4$350M to $370MGAAP Net IncomePositive during H2 2025","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}